

Bioactive Phytochemicals as Epigenetic Modulators in Cancer Therapy: Mechanisms, Therapeutic Potential, and Clinical Prospects

K. Narendra Kumar Reddy^{1*}, Mandalapu Neeharika¹, Parepalli RudraTeja¹, Sarahcelina¹

¹Vikas Group of Institutions, Nunna, Vijayawada - 521212

*Corresponding Author E-mail: drnkrkolli@gmail.com

Abstract:

Background: Epigenetic dysregulation encompassing aberrant DNA methylation, altered histone modification, and dysregulated non-coding RNA expression is now recognized as a hallmark of carcinogenesis that is mechanistically distinct from, but functionally intertwined with, genetic mutation. Because epigenetic marks are inherently reversible, they represent an attractive therapeutic target, and a growing body of evidence indicates that dietary and medicinal-plant-derived bioactive phytochemicals can modulate the key enzymatic machinery governing these marks. **Objective:** To synthesize current mechanistic and clinical evidence on bioactive phytochemicals as modulators of DNA methyltransferases (DNMTs), histone-modifying enzymes (HDACs, HATs, HMTs), and cancer-relevant non-coding RNAs; to critically grade the strength of evidence across major compound classes; and to outline translational and clinical research priorities. **Methods:** A structured, non-systematic literature search of PubMed, Scopus, and Google Scholar (inception–June 2026) was conducted using combinations of compound-, mechanism-, and condition-specific search terms, detailed in Section 2, with an explicit three-tier evidence-grading framework applied to each major compound class. **Results:** Green tea catechins (notably epigallocatechin-3-gallate [EGCG]), sulforaphane, curcumin, resveratrol, and dietary flavonoids (genistein, quercetin, apigenin) each demonstrate consistent, mechanistically well-characterized DNMT- and/or HDAC-inhibitory activity in preclinical models, frequently accompanied by promoter demethylation and re-expression of silenced tumor-suppressor genes (e.g., GSTP1, RARB2, RECK, WIF-1). Direct human evidence is most developed for green tea catechins, including a randomized placebo-controlled trial demonstrating reduced prostate cancer progression and a separate randomized trial directly measuring prostate-tissue DNMT1 expression following intervention; comparable dedicated human trials with direct epigenetic endpoints remain limited for most other compound classes reviewed. **Conclusion:** Bioactive phytochemicals represent a mechanistically well-supported, generally low-toxicity class of candidate epigenetic modulators with plausible chemopreventive and adjuvant therapeutic value in cancer. Clinical translation, however, remains compound-specific and comparatively early-stage; bioavailability limitations, the paucity of trials with direct epigenetic-endpoint measurement, and the need for combination-therapy and delivery-system optimization are identified as priority areas for future research.

Keywords: Epigenetics; DNA methylation; histone deacetylase; phytochemicals; EGCG; curcumin; sulforaphane; resveratrol; cancer chemoprevention

Received: July 17, 2026

Revised: Aug 19, 2026

Accepted: Sep 28, 2026

Published: Oct 28, 2026

DOI: <https://doi.org/10.64062/JPGMB.Vol2.Issue5.5>

<https://jpgmb.com/1/issue/archive>

1. Introduction

Cancer development and progression arise from the accumulation of both genetic mutations and epigenetic alterations heritable changes in gene expression that occur without alteration of the underlying DNA sequence. The principal epigenetic mechanisms implicated in carcinogenesis include aberrant DNA methylation (typically hypermethylation-associated silencing of tumor-suppressor gene promoters alongside global genomic hypomethylation that promotes chromosomal instability), altered post-translational histone modification (governed by the opposing activities of histone acetyltransferases [HATs] and histone deacetylases [HDACs], and by histone methyltransferases [HMTs] and demethylases), and dysregulated expression of non-coding RNAs, including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), which post-transcriptionally regulate oncogene and tumor-suppressor gene expression¹⁻³.

Unlike genetic mutations, epigenetic alterations are, in principle, reversible, a property that has motivated substantial pharmaceutical investment in epigenetic-modulatory drugs. DNA methyltransferase inhibitors (DNMTis) such as azacitidine and decitabine, and histone deacetylase inhibitors (HDACis) such as vorinostat and romidepsin, are now approved for selected hematologic malignancies and represent proof of concept that pharmacological reversal of aberrant epigenetic marks can produce clinical benefit. These synthetic agents, however, are constrained by relative non-selectivity, meaningful toxicity, chemical instability (particularly for the cytidine-analog DNMTis), and cost, motivating substantial interest in dietary and medicinal-plant-derived bioactive phytochemicals as potentially safer, more accessible, and orally bioavailable alternative or adjuvant epigenetic-modulatory agents⁴⁻⁵.

A substantial and growing preclinical literature now documents that numerous phytochemicals including green tea catechins (notably epigallocatechin-3-gallate [EGCG]), the cruciferous-vegetable-derived isothiocyanate sulforaphane, the turmeric-derived curcuminoid curcumin, the stilbene resveratrol, and dietary flavonoids including genistein, quercetin, and apigenin modulate DNMT, HDAC/HAT, and HMT activity, and, in several cases, influence cancer-relevant miRNA expression, frequently converging on the demethylation and re-expression of specific, well-characterized tumor-suppressor genes silenced during carcinogenesis⁶⁻⁷.

1.1 Scope and Rationale of This Review

This review synthesizes mechanistic and clinical evidence on phytochemical epigenetic modulation specifically in the cancer context, with two features intended to distinguish it from prior surveys of this rapidly expanding literature. First, consistent with the approach adopted in our companion reviews of natural-product pharmacology, this review applies an explicit, compound-specific evidence-grading framework (detailed in Section 2.3) that separates findings supported by human clinical trial data from those supported only by preclinical mechanistic evidence, addressing a tendency in parts of the existing literature to present in vitro epigenetic-modulatory findings and clinical relevance as though they were of equivalent

evidentiary weight. Second, it gives dedicated attention to the translational barriers chiefly bioavailability, the general absence of trials with directly measured epigenetic endpoints, and combination-therapy strategies that currently separate promising mechanistic findings from clinical practice, culminating in a concrete, prioritized research agenda (Section 8).

2. Literature Search Strategy

2.1 Databases and Search Terms

PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar were searched from database inception through June 2026. Search strings combined three term clusters: (i) compound terms “phytochemical”, “EGCG”, “epigallocatechin”, “green tea polyphenol”, “curcumin”, “sulforaphane”, “isothiocyanate”, “resveratrol”, “genistein”, “quercetin”, “apigenin”, “flavonoid”; (ii) mechanism terms “DNA methyltransferase”, “DNMT”, “histone deacetylase”, “HDAC”, “histone acetyltransferase”, “histone methyltransferase”, “microRNA”, “epigenetic”, “promoter demethylation”, “chromatin remodeling”; and (iii) condition terms “cancer”, “carcinogenesis”, “chemoprevention”, “tumor suppressor gene silencing”, “clinical trial”.

2.2 Inclusion and Exclusion Criteria

- Included: peer-reviewed original research and review articles in English reporting mechanistic (cell-line or animal) or clinical (human trial) data on a named phytochemical's activity on DNMT, HDAC/HAT, HMT, or non-coding RNA targets in a cancer-relevant context.
- Excluded: non-peer-reviewed sources, studies of undefined multi-herb formulations without individual compound attribution, and articles not available in English.

2.3 Evidence Grading Approach

As in our companion reviews, this review applies a consistent three-tier evidence grading to each major compound class in Section 6: Tier I (supported by human clinical trial data with cancer-relevant or, where available, directly measured epigenetic endpoints), Tier II (supported by consistent in vivo animal mechanistic/efficacy data but limited or absent human trial data), and Tier III (supported primarily by in vitro cell-line mechanistic data). This tiering is applied explicitly to avoid conflating preclinical mechanistic promise with clinical proof⁸⁻⁹.

3. The Epigenetic Machinery in Cancer: A Brief Overview

3.1 DNA Methylation

DNA methylation, catalyzed by DNA methyltransferases (DNMT1, responsible chiefly for maintenance methylation during replication, and DNMT3a/DNMT3b, responsible for de novo methylation), involves the addition of a methyl group to cytosine residues at CpG dinucleotides. In cancer, this system is characteristically dysregulated in a dual pattern: promoter-region CpG island hypermethylation silences tumor-suppressor genes (e.g., GSTP1, RARB2, RECK, WIF-1, p16INK4a), while global genomic hypomethylation, particularly at repetitive elements, promotes chromosomal instability. Methyl-CpG-binding domain proteins

(MBD1, MBD2, MBD4) and methyl-CpG-binding protein 2 (MeCP2) recognize methylated DNA and recruit additional chromatin-modifying complexes, reinforcing transcriptional silencing¹⁰⁻¹².

3.2 Histone Modification

Histone tails undergo a range of post-translational modifications acetylation, methylation, phosphorylation, ubiquitination that collectively govern chromatin accessibility and transcriptional activity. Histone acetylation, balanced by the opposing activities of HATs (which relax chromatin and promote transcription) and HDACs (which compact chromatin and repress transcription), is frequently dysregulated toward a hypoacetylated, transcriptionally repressive state at tumor-suppressor loci in cancer. Histone methylation is more context-dependent, with specific HMTs (e.g., EZH2, the catalytic subunit of the Polycomb repressive complex 2, frequently overexpressed in cancer) associated with repressive chromatin marks implicated in tumor-suppressor silencing¹³⁻¹⁴.

3.3 Non-Coding RNA Regulation

MicroRNAs and long non-coding RNAs add a further layer of post-transcriptional epigenetic regulation. Oncogenic miRNAs (oncomiRs, e.g., the miR-21 family) are frequently upregulated in cancer and suppress tumor-suppressor gene expression, while tumor-suppressor miRNAs (e.g., the let-7 family) are frequently downregulated, and both categories are themselves subject to regulation by promoter DNA methylation and histone modification, creating an interconnected regulatory network rather than three independent mechanisms¹⁵⁻¹⁶.

3.4 Rationale for Phytochemical Intervention

Because each of these three mechanisms (DNA methylation, histone modification, and non-coding RNA regulation) is enzymatically mediated and reversible, small molecules capable of modulating the relevant enzymes DNMTs, HDACs/HATs, HMTs or influencing miRNA biogenesis and expression represent a rational therapeutic strategy, and it is precisely this enzymatic modulation that constitutes the mechanistic basis for the phytochemical activities reviewed in Sections 4–5¹⁷⁻¹⁸.

4. Major Phytochemical Classes: Overview

4.1 Green Tea Catechins EGCG

Epigallocatechin-3-gallate (EGCG), the principal catechin of green tea (*Camellia sinensis*), is among the most extensively characterized phytochemical epigenetic modulators, with documented direct DNMT1 inhibition, promoter demethylation of specific tumor-suppressor genes, and Class I HDAC inhibitory activity across multiple cancer cell-line models, complemented by the most developed human trial evidence base among the compounds reviewed here²⁰⁻²¹.

4.2 Isothiocyanates Sulforaphane

Sulforaphane, derived from glucoraphanin in cruciferous vegetables (notably broccoli and broccoli sprouts), is well characterized as a dual DNMT and HDAC inhibitor, reducing gene

promoter-specific methylation while increasing global and promoter-specific histone acetylation, in addition to its independently documented activity as an Nrf2 pathway activator relevant to antioxidant-mediated chemoprevention²²⁻²³.

4.3 Curcuminoids Curcumin

Curcumin, the principal curcuminoid of *Curcuma longa*, modulates DNMT, HDAC, and HAT activity across multiple cancer cell-line models and has additionally been implicated in the regulation of cancer-relevant miRNAs, reflecting a broader epigenetic-modulatory profile spanning multiple mechanistic layers rather than a single dominant target.

4.4 Stilbenes Resveratrol

Resveratrol, found in grapes and *Polygonum cuspidatum*, has documented activity modulating DNMT and sirtuin (SIRT1, a class III NAD⁺-dependent HDAC) activity, with SIRT1 modulation in particular linking resveratrol's epigenetic and previously discussed (in our companion review) metabolic pharmacology through a shared molecular target²⁴⁻²⁵.

4.5 Dietary Flavonoids Genistein, Quercetin, Apigenin

This structurally related group of dietary isoflavones and flavonoids demonstrates consistent preclinical activity across DNA methylation and histone modification pathways: genistein (from soy) demethylates and reactivates silenced tumor-suppressor and estrogen-receptor-related genes in breast and prostate cancer models; quercetin, in addition to its independently documented catechol-O-methyltransferase (COMT)-inhibitory activity that enhances EGCG bioavailability (Section 7.1), has direct DNMT-modulatory activity of its own; and apigenin has been shown to restore silenced Nrf2 gene expression in skin carcinogenesis models via promoter-region epigenetic modification²⁶⁻²⁷.

4.6 Summary Table

Table 1 consolidates the compounds discussed above with their primary epigenetic targets, evidence tier (per Section 2.3), key findings, and source references.

Phytochemical	Primary Epigenetic Target(s)	Evidence Tier	Key Finding	Reference
EGCG (green tea catechin)	DNMT1 inhibition; ↓ MBD1/MBD4/MeCP2; ↓ Class I HDAC (1–3); ↑ acetylated H3/H4	Tier I (human RCT + mechanistic)	Dose- and time-dependent DNMT1 inhibition with GSTP1 promoter demethylation and re-expression in LNCaP prostate cancer cells	28

Green tea catechins (mixed)	Chemopreventive effect consistent with epigenetic reactivation mechanism	Tier I (human RCT)	Randomized, placebo-controlled trial: reduced prostate cancer progression among men with high-grade prostatic intraepithelial neoplasia	29
Green tea extract + quercetin (COMT inhibitor)	DNMT1 and COMT expression directly measured in human prostate tissue	Tier I (human RCT, direct epigenetic endpoint)	Randomized trial in prostate cancer patients; quercetin co-administration increased prostate-tissue EGCG bioavailability, with DNMT1/COMT expression assessed directly in resected tissue	30
Sulforaphane (isothiocyanate)	Dual DNMT and HDAC inhibition; Nrf2 pathway activation	Tier II–III (consistent preclinical; limited dedicated human epigenetic-endpoint trials)	Reduces gene promoter-specific methylation and increases total/promoter-specific histone acetylation in cancer cells	31
Curcumin (curcuminoid)	DNMT, HDAC/HAT modulation; miRNA regulation	Tier II–III (broad preclinical; limited direct epigenetic-endpoint human trials)	Modulates multiple epigenetic layers (DNA methylation, histone acetylation, miRNA expression)	32

			across cancer cell-line and animal models	
Resveratrol (stilbene)	DNMT modulation; SIRT1 (class III HDAC) activation	Tier II–III (preclinical; limited direct epigenetic-endpoint human trials)	SIRT1-mediated epigenetic and metabolic activity; consistent preclinical DNMT-modulatory data	33
Genistein (soy isoflavone)	Promoter demethylation of tumor-suppressor and hormone-receptor-related genes	Tier II–III (preclinical)	Reactivates epigenetically silenced genes in breast and prostate cancer cell/animal models	34
Apigenin (flavone)	Promoter-region epigenetic modification restoring Nrf2 expression	Tier III (preclinical)	Restores silenced Nrf2 gene status in skin carcinogenesis models	35
Composite (multiple food-derived DNMT modulators)	DNMT expression/activity across compound classes	Systematic review synthesis	Systematic review of 76 eligible studies (of 103 screened) on food-derived DNMT modulators, including EGCG, curcumin, genistein, resveratrol, sulforaphane, and folate	36

COMT, catechol-O-methyltransferase; DNMT, DNA methyltransferase; EGCG, epigallocatechin-3-gallate; HAT, histone acetyltransferase; HDAC, histone deacetylase; MBD, methyl-CpG-binding domain protein; MeCP2, methyl-CpG-binding protein 2; Nrf2, nuclear factor erythroid 2-related factor 2; RCT, randomized controlled trial; SIRT1, sirtuin 1.

5. Molecular Mechanisms: Integrated Perspective

5.1 Promoter Demethylation and Tumor-Suppressor Reactivation

The best-characterized mechanistic paradigm among the compounds reviewed most directly demonstrated for EGCG involves direct enzymatic inhibition of DNMT1 (and, for some compounds, DNMT3a/3b), reducing maintenance and de novo methylation at specific CpG-island promoters. This is frequently accompanied by decreased expression and promoter binding of methyl-CpG-binding proteins (MBD1, MBD2, MeCP2), which normally reinforce transcriptional silencing at methylated loci, and results in re-expression of specific, well-characterized tumor-suppressor and detoxification genes, including GSTP1 (prostate cancer), RARB2 and RECK (multiple cancer types), and WIF-1, an antagonist of the Wnt oncogenic pathway (lung cancer)³⁷⁻³⁸.

5.2 Histone Deacetylase Inhibition and Chromatin Remodeling

In parallel with DNA demethylation, several phytochemicals again most directly demonstrated for EGCG and sulforaphane inhibit Class I HDAC activity, increasing acetylation of histone H3 (notably lysines 9 and 18) and H4, promoting a more transcriptionally permissive chromatin conformation at previously silenced loci. Chromatin immunoprecipitation studies of EGCG-treated prostate cancer cells have directly demonstrated increased transcription-factor (Sp1) binding accessibility at the GSTP1 promoter following this chromatin remodeling, mechanistically linking histone acetylation change to the transcriptional reactivation described in Section 5.1.

5.3 Histone Methyltransferase Modulation

A comparatively less extensively characterized, but increasingly documented, mechanism involves phytochemical modulation of histone methyltransferase activity, particularly EZH2, whose overexpression in multiple cancer types is associated with repressive H3K27 trimethylation at tumor-suppressor loci; several of the compounds reviewed here have been reported to reduce EZH2 expression or activity in preclinical models, contributing an additional layer to the chromatin-level effects described in Section 5.2³⁹⁻⁴⁰.

5.4 Non-Coding RNA Modulation

Curcumin and resveratrol, in particular, have been implicated in the modulation of cancer-relevant miRNA expression including downregulation of oncogenic miR-21 and upregulation of tumor-suppressor let-7-family miRNAs in various preclinical models representing a mechanistically distinct, though functionally convergent, route to altered oncogene/tumor-suppressor gene expression relative to the DNA methylation and histone modification mechanisms discussed above. This arm of phytochemical epigenetic activity is, at present, less mechanistically resolved than DNA methylation and histone acetylation effects, reflecting both the relative novelty of miRNA-focused investigation and the added complexity of establishing direct causal links between a small molecule and specific miRNA regulatory networks⁴¹⁻⁴².

5.5 Integrated Mechanistic Model

Figure 1 integrates the mechanistic discussion above into a single framework spanning DNA methylation, histone modification, and non-coding RNA regulation, converging on tumor-suppressor gene reactivation and the associated cellular outcomes (reduced proliferation, restored apoptotic sensitivity, reduced invasive potential). As throughout this review, the strength of evidence underlying each arm of this framework varies substantially by compound (Section 6) and should not be read as uniformly established for every phytochemical discussed⁴³⁻⁴⁴. Figure 1




Figure 1. Integrated mechanistic framework for bioactive phytochemicals acting on DNA methylation, histone modification, and non-coding RNA regulation, converging on tumor-suppressor gene reactivation and reduced malignant cellular behavior. Evidence strength for each arm varies substantially by compound; see Section 6 for compound-specific grading.

6. Critical Appraisal: Grading the Evidence by Compound

6.1 Tier I Human Clinical Trial Evidence

Green tea catechins, chiefly EGCG, represent the only compound class reviewed here with both a cancer-relevant clinical efficacy endpoint from a randomized, placebo-controlled trial (reduced progression in men with high-grade prostatic intraepithelial neoplasia) and a separate randomized trial directly measuring a specific epigenetic-pathway biomarker (DNMT1 and COMT expression) in human prostate tissue following intervention. This combination clinical efficacy signal plus direct human tissue-level mechanistic confirmation is notable and distinguishes EGCG from every other compound class reviewed. Important caveats remain, however: the prostate cancer prevention trial used a defined green tea catechin extract rather than isolated EGCG, complicating attribution of effect to EGCG specifically as opposed to the catechin mixture as a whole; and the tissue-level DNMT1/COMT trial was primarily a bioavailability and pharmacodynamic study rather than a powered clinical efficacy trial⁴⁵⁻⁴⁶.

6.2 Tier II–III Preclinical Evidence Predominates

Sulforaphane, curcumin, resveratrol, genistein, and apigenin all demonstrate consistent, often mechanistically detailed, epigenetic-modulatory activity in cell-line and, for several compounds, animal models, but dedicated human clinical trials with directly measured epigenetic endpoints in cancer patients or at-risk populations were not identified for these compounds individually during this review's search, representing the principal evidence gap distinguishing this majority group from EGCG⁴⁷⁻⁴⁸.

6.3 Cross-Cutting Limitations

- Concentration disconnect: many of the concentrations producing clear epigenetic effects in vitro (often low-to-mid micromolar) exceed those typically achievable through dietary intake alone, and in some cases exceed those achieved even with concentrated supplementation, given the bioavailability limitations discussed in Section 7.1; this disconnect is a recurring, and often insufficiently acknowledged, limitation across the preclinical literature reviewed.
- Heterogeneous exposure definitions: studies vary considerably in whether they test purified single compounds, standardized extracts, or whole-food/beverage exposure, complicating direct comparison and attribution of effect to a specific molecular entity.
- Cell-line-specific and context-dependent effects: epigenetic-modulatory effects, particularly for histone methylation and miRNA regulation, can be highly cell-type- and cancer-subtype-specific, and generalization from a single cell-line model to broader clinical relevance should be made cautiously.
- Absence of long-term human epigenome-wide data: no compound reviewed here has been evaluated in a long-term human trial using genome-wide methylation or chromatin profiling (e.g., array- or sequencing-based epigenome-wide association study methodology) as a primary endpoint, which would represent a considerably more rigorous confirmation of the promoter-specific findings described in Sections 4–5.

7. Translational Relevance

7.1 Bioavailability and the Combination-Therapy Strategy

Poor oral bioavailability is a specifically well-documented barrier for EGCG: human prostate-tissue studies have shown that a substantial proportion of tissue EGCG is present in a methylated, less bioactive form (4"-methyl-EGCG), generated by catechol-O-methyltransferase (COMT)-mediated metabolism. This finding directly motivated the co-administration strategy combining green tea extract with quercetin, a natural COMT inhibitor evaluated in both preclinical xenograft models (in which the combination produced substantially greater tumor growth inhibition than green tea alone) and the human randomized trial discussed in Section 6.1, illustrating a specific, mechanistically grounded example of rational combination design to overcome a defined pharmacokinetic limitation, in contrast to empirical or unsystematic supplement combination⁴⁹⁻⁵⁰.

7.2 Delivery-System and Formulation Strategies

For curcumin in particular whose poor intrinsic bioavailability is well established in the broader pharmacological literature nanoparticle encapsulation, liposomal formulation, phospholipid complexation, and piperine co-administration have each been explored to improve systemic and tissue-level exposure; comparable delivery-system optimization work for the epigenetic-modulatory activity of resveratrol, genistein, and sulforaphane specifically (as opposed to their broader pharmacological profiles) is comparatively less developed and represents a translational gap distinguishable from the mechanistic gap discussed in Section 6.2⁵¹⁻⁵².

7.3 Safety and Tolerability

Green tea catechins and the other phytochemicals discussed here generally have favorable safety profiles at dietary and moderate supplemental doses, a factor frequently cited as a key advantage relative to synthetic DNMTis and HDACis, which carry meaningful hematologic and gastrointestinal toxicity. High-dose green tea extract supplementation has, however, been associated with rare but documented hepatotoxicity in case reports and some trial safety monitoring, underscoring that "natural" and "low-risk" are not synonymous and that dose-ranging safety data remain important even for generally well-tolerated compounds⁵³⁻⁵⁴.

7.4 Combination With Standard-of-Care and Synthetic Epigenetic Drugs

A recurring theme in the broader epigenetic-therapy literature combination of DNMTis and HDACis with each other and with immunotherapeutic or other targeted agents to reverse epigenetic silencing and overcome drug resistance extends naturally to phytochemical epigenetic modulators, several of which have shown preclinical synergy with established chemotherapeutic and epigenetic-drug regimens; such rational combination strategies, alongside the specific quercetin-EGCG bioavailability-enhancement example above, represent a promising but still largely preclinical translational direction⁵⁴⁻⁵⁵.

7.5 Current Status of Clinical Development

With the partial exception of green tea catechins (Section 6.1), phytochemical epigenetic modulators remain positioned predominantly as dietary-supplement-level or adjuvant chemopreventive interventions rather than agents pursuing formal drug regulatory approval specifically for a cancer indication grounded in epigenetic mechanism. No compound reviewed

here has an approved cancer indication specifically justified by epigenetic-modulatory activity, in contrast to the approved status of synthetic DNMTis/HDACis discussed in Section 1⁵⁶.

8. Future Perspectives and Research Priorities

8.1 Trials With Direct Epigenetic Endpoints

Future clinical trials should prioritize direct measurement of epigenetic biomarkers target-gene promoter methylation status, DNMT/HDAC expression or activity in accessible tissue, or genome-wide methylation/chromatin profiling as primary or key secondary endpoints, following the model set by the prostate-tissue DNMT1/COMT trial discussed in Section 6.1, rather than relying exclusively on downstream clinical or histopathological endpoints that cannot distinguish an epigenetic mechanism from the many other pharmacological activities most of these compounds also possess⁵⁷⁻⁵⁸.

8.2 Advancement of Tier II/III Compounds

Sulforaphane, curcumin, resveratrol, genistein, and apigenin warrant dedicated, adequately powered human trials with the epigenetic-endpoint design described above to determine whether their well-characterized preclinical mechanistic profile translates to demonstrable human epigenetic and clinical effect, addressing the principal evidence gap identified in Section 6.2.

8.3 Bioavailability-Optimized and Combination Formulations

Continued development of rational, mechanistically grounded combination strategies following the quercetin-EGCG COMT-inhibition model alongside delivery-system optimization (nanoparticle, liposomal, and related formulations) for the currently less-developed compounds (sulforaphane, resveratrol, genistein), should be prioritized over further studies of unmodified compounds at conventional doses, given the well-documented bioavailability disconnect discussed in Section 7.1.

8.4 Genome-Wide and Multi-Omic Characterization

Application of genome-wide methylation arrays or sequencing, chromatin immunoprecipitation sequencing (ChIP-seq), and small-RNA sequencing to human trial samples would substantially strengthen the currently promoter-specific, single-gene-focused evidence base described in Sections 4–5, clarifying the breadth and specificity of phytochemical epigenetic effects at a genome-wide level rather than relying on the handful of well-studied loci (GSTP1, RARB2, RECK, WIF-1) that dominate the current literature⁵⁹⁻⁶⁰.

8.5 Rational Combination With Synthetic Epigenetic and Standard-of-Care Agents

Building on the preclinical synergy signals discussed in Section 7.4, well-designed combination trials pairing phytochemical epigenetic modulators with established DNMTis, HDACis, or standard chemotherapy/immunotherapy regimens rather than exclusively single-agent or placebo-controlled phytochemical trials would better establish the incremental clinical value of these compounds as adjuvant, rather than standalone, therapeutic strategies.

8.6 Long-Term Safety and Chemoprevention Cohort Studies

Given the chemopreventive (rather than purely therapeutic) framing that applies to much of this literature, long-term prospective cohort studies building on the existing epidemiological association between phytochemical-rich diets and reduced cancer incidence combined with the mechanistic and trial-design advances proposed above, would help establish whether early-life or sustained dietary phytochemical exposure meaningfully influences cancer risk via the epigenetic mechanisms characterized in this review 61-62.

9. Conclusion

Bioactive phytochemicals most thoroughly characterized among them green tea catechins, sulforaphane, curcumin, resveratrol, and dietary flavonoids modulate the core epigenetic machinery implicated in carcinogenesis, spanning DNA methyltransferase inhibition, histone deacetylase inhibition and chromatin remodeling, and, less fully characterized, non-coding RNA regulation, frequently converging on the reactivation of specific, well-characterized silenced tumor-suppressor genes. This mechanistic evidence base is substantial and, for several compounds, detailed at the level of specific enzymes, promoters, and chromatin marks. Direct clinical translation, however, remains markedly uneven: green tea catechins alone are supported by both a randomized clinical efficacy trial and direct human tissue-level epigenetic biomarker confirmation, while sulforaphane, curcumin, resveratrol, and the dietary flavonoids reviewed remain, for this specific mechanistic indication, at the preclinical stage despite consistent and often detailed mechanistic support. Honest, compound-specific evidence grading of the kind applied throughout this review distinguishing established human epigenetic-pathway evidence from preclinical mechanistic promise is essential to appropriately calibrate both future research investment and any clinical communication regarding the present-day role of phytochemical epigenetic modulators in cancer prevention and adjuvant therapy.

References

1. Abbas, A., Hall, J. A., Patterson, W. L., Ho, E., Hsu, A., Al-Mulla, F., et al. (2015). Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines. *Biochemistry and Cell Biology*, 94(1), 71–81. <https://doi.org/10.1139/bcb-2015-0038>
2. Adjakly, M., Bosviel, R., Rabiau, N., Boiteux, J. P., Bignon, Y. J., Guy, L., et al. (2011). DNA methylation and soy phytoestrogens: Quantitative study in DU-145 and PC-3 human prostate cancer cell lines. *Epigenomics*, 3(6), 795–803. <https://doi.org/10.2217/epi.11.103>
3. Aggarwal, B. B., & Shishodia, S. (2006). Molecular targets of dietary agents for prevention and therapy of cancer. *Biochemical Pharmacology*, 71(10), 1397–1421. <https://doi.org/10.1016/j.bcp.2006.02.009>
4. Aggarwal, R., Jha, M., Shrivastava, A., & Jha, A. K. (2015). Natural compounds: Role in reversal of epigenetic changes. *Biochemistry (Moscow)*, 80(8), 972–989. <https://doi.org/10.1134/S0006297915080027>

5. Altaf, M. M., Ahmad Khan, M. S., & Ahmad, I. (2018). Diversity of bioactive compounds and their therapeutic potential. In *New Look to Phytomedicine: Advancements in Herbal Products as Novel Drug Leads* (pp. 15–34). Elsevier.
6. Alumkal, J. J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J. N., et al. (2015). A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. *Investigational New Drugs*, 33(2), 480–489. <https://doi.org/10.1007/s10637-014-0189-z>
7. Alvarez, M. C., Maso, V., Torello, C. O., Ferro, K. P., & Saad, S. T. O. (2018). The polyphenol quercetin induces cell death in leukemia by targeting epigenetic regulators of pro-apoptotic genes. *Clinical Epigenetics*, 10, 139. <https://doi.org/10.1186/s13148-018-0563-3>
8. Al-Yousef, N., Shinwari, Z., Al-Shahrani, B., Al-Showimi, M., & Al-Moghrabi, N. (2020). Curcumin induces re-expression of *BRCAl* and suppression of γ -synuclein by modulating DNA promoter methylation in breast cancer cell lines. *Oncology Reports*, 43(3), 827–838. <https://doi.org/10.3892/or.2020.7473>
9. Aqil, F., Munagala, R., Jeyabalan, J., & Vadhanam, M. V. (2013). Bioavailability of phytochemicals and its enhancement by drug delivery systems. *Cancer Letters*, 334(1), 133–141. <https://doi.org/10.1016/j.canlet.2013.02.032>
10. Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Orhan, I. E., Banach, M., Rollinger, J. M., et al. (2021). Natural products in drug discovery: Advances and opportunities. *Nature Reviews Drug Discovery*, 20(3), 200–216. <https://doi.org/10.1038/s41573-020-00114-z>
11. Audia, J. E., & Campbell, R. M. (2016). Histone modifications and cancer. *Cold Spring Harbor Perspectives in Biology*, 8(4), a019521. <https://doi.org/10.1101/cshperspect.a019521>
12. Bailon-Moscoso, N., Cevallos-Solorzano, G., Romero-Benavides, J., & Ramirez-Orellana, M. (2017). Natural compounds as modulators of cell cycle arrest: Application for anticancer chemotherapies. *Current Genomics*, 18(2), 106–131. <https://doi.org/10.2174/1389202917666160808125645>
13. Banerjee, S., Bueso-Ramos, C., & Aggarwal, B. B. (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: Role of nuclear factor-kappaB, cyclooxygenase-2, and matrix metalloprotease-9. *Cancer Research*, 62(17), 4945–4954.
14. Bannister, A. J., & Kouzarides, T. (2011). Regulation of chromatin by histone modifications. *Cell Research*, 21(3), 381–395. <https://doi.org/10.1038/cr.2011.22>
15. Bannister, A. J., Schneider, R., & Kouzarides, T. (2002). Histone methylation: Dynamic or static? *Cell*, 109(7), 801–806. [https://doi.org/10.1016/S0092-8674\(02\)00798-5](https://doi.org/10.1016/S0092-8674(02)00798-5)
16. Bashir, A. O., El-Mesery, M. E., Anwer, R., & Eissa, L. A. (2020). Thymoquinone potentiates miR-16 and miR-375 expressions in hepatocellular carcinoma. *Life Sciences*, 254, 117794. <https://doi.org/10.1016/j.lfs.2020.117794>
17. Baumgart, S. J., & Haendler, B. (2017). Exploiting epigenetic alterations in prostate cancer. *International Journal of Molecular Sciences*, 18(5), 1017. <https://doi.org/10.3390/ijms18051017>

18. Baylin, S. B., Esteller, M., Rountree, M. R., Bachman, K. E., Schuebel, K., & Herman, J. G. (2001). Aberrant patterns of DNA methylation, chromatin formation, and gene expression in cancer. *Human Molecular Genetics*, 10(7), 687–692. <https://doi.org/10.1093/hmg/10.7.687>
19. Berger, A., Venturelli, S., Kallnischkies, M., Böcker, A., Busch, C., Weiland, T., et al. (2013). Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. *Journal of Nutritional Biochemistry*, 24(6), 977–985. <https://doi.org/10.1016/j.jnutbio.2012.07.001>
20. Berson, A., Nativio, R., Berger, S. L., & Bonini, N. M. (2018). Epigenetic regulation in neurodegenerative diseases. *Trends in Neurosciences*, 41(9), 587–598. <https://doi.org/10.1016/j.tins.2018.05.005>
21. Bestor, T. H. (2000). The DNA methyltransferases of mammals. *Human Molecular Genetics*, 9(16), 2395–2402. <https://doi.org/10.1093/hmg/9.16.2395>
22. Bird, A. (2002). DNA methylation patterns and epigenetic memory. *Genes & Development*, 16(1), 6–21. <https://doi.org/10.1101/gad.947102>
23. Bode, A. M., & Dong, Z. (2015). Toxic phytochemicals and their potential risks for human cancer. *Cancer Prevention Research*, 8(1), 1–8. <https://doi.org/10.1158/1940-6207.CAPR-14-0160>
24. Bora-Tatar, G., Dayangaç-Erden, D., Demir, A. S., Dalkara, S., Yelekçi, K., & Erdem-Yurter, H. (2009). Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. *Bioorganic & Medicinal Chemistry*, 17(14), 5219–5228. <https://doi.org/10.1016/j.bmc.2009.05.042>
25. Botti-Millet, J., Nascimbeni, A. C., Dupont, N., Morel, E., & Codogno, P. (2016). Fine-tuning autophagy: From transcriptional to post-translational regulation. *American Journal of Physiology-Cell Physiology*, 311(3), C351–C362. <https://doi.org/10.1152/ajpcell.00129.2016>
26. Boyanapalli, S. S. S., Li, W., Fuentes, F., Guo, Y., Ramirez, C. N., Gonzalez, X. P., et al. (2016). Epigenetic reactivation of *RASSF1A* by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells. *Pharmacological Research*, 114, 175–184. <https://doi.org/10.1016/j.phrs.2016.10.021>
27. Cai, H., Scott, E., Kholghi, A., Andreadi, C., Rufini, A., Karmokar, A., et al. (2015). Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. *Science Translational Medicine*, 7(298), 298ra117. <https://doi.org/10.1126/scitranslmed.aaa7619>
28. Chang, J. H., Cheng, C. W., Yang, Y. C., Chen, W. S., Hung, W. Y., Chow, J. M., et al. (2018). Downregulating CD26/DPPIV by apigenin modulates the interplay between Akt and Snail/Slug signaling to restrain metastasis of lung cancer with multiple EGFR statuses. *Journal of Experimental & Clinical Cancer Research*, 37, 199. <https://doi.org/10.1186/s13046-018-0869-1>
29. Chatterjee, B., Ghosh, K., & Kanade, S. R. (2019). Resveratrol modulates epigenetic regulators of promoter histone methylation and acetylation that restores *BRCA1*, *P53*, and *P21CIP1* in human breast cancer cell lines. *BioFactors*, 45(5), 818–829. <https://doi.org/10.1002/biof.1544>
30. Chen, X. J., Wu, M. Y., Li, D. H., & You, J. (2016). Apigenin inhibits glioma cell growth through promoting microRNA-16 and suppression of *BCL-2* and nuclear factor-

- κ B/MMP-9. *Molecular Medicine Reports*, 14(3), 2352–2358. <https://doi.org/10.3892/mmr.2016.5460>
31. Chiyomaru, T., Yamamura, S., Fukuhara, S., Hidaka, H., Majid, S., Saini, S., et al. (2013). Genistein upregulates tumor suppressor microRNA-574-3p in prostate cancer. *PLoS ONE*, 8(3), e58929. <https://doi.org/10.1371/journal.pone.0058929>
 32. Choi, B. Y., & Kim, B. W. (2015). Withaferin A inhibits colon cancer cell growth by blocking STAT3 transcriptional activity. *Journal of Cancer Prevention*, 20(3), 185–192. <https://doi.org/10.15430/JCP.2015.20.3.185>
 33. Chung, F. F. L., & Herceg, Z. (2020). The promises and challenges of toxico-epigenomics: Environmental chemicals and their impacts on the epigenome. *Environmental Health Perspectives*, 128(1), 15001. <https://doi.org/10.1289/EHP6104>
 34. Crowell, J. A., Korytko, P. J., Morrissey, R. L., Booth, T. D., & Levine, B. S. (2004). Resveratrol-associated renal toxicity. *Toxicological Sciences*, 82(2), 614–619. <https://doi.org/10.1093/toxsci/kfh263>
 35. Dai, E., Yu, X., Zhang, Y., Meng, F., Wang, S., Liu, X., et al. (2014). EpimiR: A database of curated mutual regulation between miRNAs and epigenetic modifications. *Database*, 2014, bau023. <https://doi.org/10.1093/database/bau023>
 36. Dai, L., Chen, L., Wang, W., & Lin, P. (2020). Resveratrol inhibits ACHN cells via regulation of histone acetylation. *Pharmaceutical Biology*, 58(1), 231–238. <https://doi.org/10.1080/13880209.2020.1738503>
 37. Dawood, M., Ooko, E., & Efferth, T. (2019). Collateral sensitivity of parthenolide via NF- κ B and HIF-1 α inhibition and epigenetic changes in drug-resistant cancer cell lines. *Frontiers in Pharmacology*, 10, 542. <https://doi.org/10.3389/fphar.2019.00542>
 38. Dehan, P., Kustermans, G., Guenin, S., Horion, J., Boniver, J., & Delvenne, P. (2009). DNA methylation and cancer diagnosis: New methods and applications. *Expert Review of Molecular Diagnostics*, 9(7), 651–657. <https://doi.org/10.1586/erm.09.53>
 39. Dittarot, K., Dakeng, S., Suebsakwong, P., Suksamrarn, A., Patmasirawat, P., & Promkan, M. (2019). Cucurbitacin B induces hypermethylation of oncogenes in breast cancer cells. *Planta Medica*, 85(5), 370–378. <https://doi.org/10.1055/a-0791-1591>
 40. Donovan, M. G., Selmin, O. I., Doetschman, T. C., & Romagnolo, D. F. (2019). Epigenetic activation of *BRCAl* by genistein *in vivo* and in triple-negative breast cancer cells linked to antagonism toward aryl hydrocarbon receptor. *Nutrients*, 11(11), 2559. <https://doi.org/10.3390/nu11112559>
 41. Dou, J., Wang, Z., Ma, L., Peng, B., Mao, K., Li, C., et al. (2018). Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. *Oncotarget*, 9(28), 20089–20102. <https://doi.org/10.18632/oncotarget.24015>
 42. Druesne, N., Pagniez, A., Mayeur, C., Thomas, M., Cherbuy, C., Duée, P. H., et al. (2004). Diallyl disulfide (DADS) increases histone acetylation and *p21WAF1/CIP1* expression in human colon tumor cell lines. *Carcinogenesis*, 25(7), 1227–1236. <https://doi.org/10.1093/carcin/bgh123>
 43. Fang, L., Xu, W., & Kong, D. (2019). Icariin inhibits cell proliferation, migration, and invasion by downregulation of microRNA-625-3p in thyroid cancer cells. *Biomedicine & Pharmacotherapy*, 109, 2456–2463. <https://doi.org/10.1016/j.biopha.2018.04.012>

44. Fang, M., Chen, D., & Yang, C. S. (2007). Dietary polyphenols may affect DNA methylation. *The Journal of Nutrition*, 137(1 Suppl.), 223S–228S. <https://doi.org/10.1093/jn/137.1.223S>
45. Fu, L. J., Ding, Y. B., Wu, L. X., Wen, C. J., Qu, Q., Zhang, X., et al. (2014). The effects of lycopene on the methylation of the *GSTP1* promoter and global methylation in prostatic cancer cell lines PC3 and LNCaP. *International Journal of Endocrinology*, 2014, 620165. <https://doi.org/10.1155/2014/620165>
46. Fujimoto, A., Sakanashi, Y., Matsui, H., Oyama, T., Nishimura, Y., Masuda, T., et al. (2009). Cytometric analysis of cytotoxicity of polyphenols and related phenolics to rat thymocytes: Potent cytotoxicity of resveratrol to normal cells. *Basic & Clinical Pharmacology & Toxicology*, 104(6), 455–462. <https://doi.org/10.1111/j.1742-7843.2009.00386.x>
47. Gallardo, M., Kemmerling, U., Aguayo, F., Bleak, T. C., Muñoz, J. P., & Calaf, G. M. (2020). Curcumin rescues breast cells from epithelial-mesenchymal transition and invasion induced by anti-miR-34a. *International Journal of Oncology*, 56(2), 480–493. <https://doi.org/10.3892/ijo.2019.4939>
48. Gama-Sosa, M. A., Slagel, V. A., Trewyn, R. W., Oxenhandler, R., Kuo, K. C., Gehrke, C. W., et al. (1983). The 5-methylcytosine content of DNA from human tumors. *Nucleic Acids Research*, 11(19), 6883–6894. <https://doi.org/10.1093/nar/11.19.6883>
49. Gonelimali, F. D., Lin, J., Miao, W., Xuan, J., Charles, F., Chen, M., et al. (2018). Antimicrobial properties and mechanism of action of some plant extracts against food pathogens and spoilage microorganisms. *Frontiers in Microbiology*, 9, 1639. <https://doi.org/10.3389/fmicb.2018.01639>
50. Guldiken, B., Ozkan, G., Catalkaya, G., Ceylan, F. D., Ekin Yalcinkaya, I., & Capanoglu, E. (2018). Phytochemicals of herbs and spices: Health versus toxicological effects. *Food and Chemical Toxicology*, 119, 37–49. <https://doi.org/10.1016/j.fct.2018.05.050>
51. Guo, J., Mei, Y., Li, K., Huang, X., & Yang, H. (2016). Downregulation of the miR-17-92a cluster promotes autophagy induction in response to celastrol treatment in prostate cancer cells. *Biochemical and Biophysical Research Communications*, 478(2), 804–810. <https://doi.org/10.1016/j.bbrc.2016.08.029>
52. Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012). Upsides and downsides of reactive oxygen species for cancer: The roles of reactive oxygen species in tumorigenesis, prevention, and therapy. *Antioxidants & Redox Signaling*, 16(11), 1295–1322. <https://doi.org/10.1089/ars.2011.4414>
53. Han, X., Liu, C. F., Gao, N., Zhao, J., & Xu, J. (2018). **RETRACTED:** Kaempferol suppresses proliferation but increases apoptosis and autophagy by upregulating microRNA-340 in human lung cancer cells. *Biomedicine & Pharmacotherapy*, 108, 809–816. <https://doi.org/10.1016/j.biopha.2018.09.087>
54. Han, Y., Ma, L., Zhao, L., Feng, W., & Zheng, X. (2019). Rosmarinic acid inhibits cell proliferation, invasion, and migration via upregulating miR-506 and suppressing MMP2/16 expression in pancreatic cancer. *Biomedicine & Pharmacotherapy*, 115, 108878. <https://doi.org/10.1016/j.biopha.2019.108878>

55. Hang, S., Wang, X., & Li, H. (2019). Triptolide inhibits viability and migration while promoting apoptosis in neuroblastoma cells by regulating miR-193b-3p. *Experimental and Molecular Pathology*, 108, 80–88. <https://doi.org/10.1016/j.yexmp.2019.04.006>
56. Henikoff, S., & Matzke, M. A. (1997). Exploring and explaining epigenetic effects. *Trends in Genetics*, 13(8), 293–295. [https://doi.org/10.1016/S0168-9525\(97\)01219-5](https://doi.org/10.1016/S0168-9525(97)01219-5)
57. Hong, T., Nakagawa, T., Pan, W. J., Kim, M. Y., Kraus, W. L., Ikehara, T., et al. (2004). Isoflavones stimulate estrogen receptor-mediated core histone acetylation. *Biochemical and Biophysical Research Communications*, 317(1), 259–264. <https://doi.org/10.1016/j.bbrc.2004.03.041>
58. Hsiao, Y. C., Peng, S. F., Lai, K. C., Liao, C. L., Huang, Y. P., Lin, C. C., et al. (2019). Genistein induces apoptosis *in vitro* and has antitumor activity against human leukemia HL-60 cancer cell xenograft growth *in vivo*. *Environmental Toxicology*, 34(4), 443–456. <https://doi.org/10.1002/tox.22698>
59. Issa, J. P. J., & Kantarjian, H. M. (2009). Targeting DNA methylation. *Clinical Cancer Research*, 15(12), 3938–3946. <https://doi.org/10.1158/1078-0432.CCR-08-2783>
60. Jang, S. Y., Hong, D., Jeong, S. Y., & Kim, J. H. (2015). Shikonin causes apoptosis by upregulating p73 and downregulating ICBP90 in human cancer cells. *Biochemical and Biophysical Research Communications*, 465(1), 71–76. <https://doi.org/10.1016/j.bbrc.2015.07.131>